Big Pharma Finds New Pipeline Source: Each Other
Executive Summary
As Big Pharma's pipeline crunch continues, so does competition for late-stage licensing opportunities, driving up late-stage deal values. A notable trend behind these rising values is a spate of Big Pharma cross-licensing deals.